I can say this article rings very true. I am generally very impressed by the accuracy of the points raised.
But make sure not to associate all PBMs with this practice. We too don't like it.
I am pretty high up at a PBM (not one of the big three), and can say our model does not play the same games (crimes!).
The point about MAC pricing is not exactly fair however. Some customers prefer to engage this way since it reflects revenue based solely on the usage of medications prescribed. It might sound odd, but this way we reduce (or near zero) other fees that we charge the customer. In general, we DONT recommend this model, but in some cases, it makes sense.
I have to stay anon, since I don't speak officially for the company; all opinions are my own.